Search

Pharma Mar SA

Closed

73.9 -3.15

Overview

Share price change

24h

Current

Min

73.55

Max

74

Key metrics

By Trading Economics

Income

27M

23M

Sales

18M

56M

P/E

Sector Avg

32.604

37.461

EPS

1.33

Dividend yield

1.01

Profit margin

41.41

Employees

500

EBITDA

27M

26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+61.51% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.01%

2.33%

Next Earnings

30 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-86M

1.4B

Previous open

77.05

Previous close

73.9

Technical Score

By Trading Central

Confidence

Bearish Evidence

Pharma Mar SA Chart

Past performance is not a reliable indicator of future results.

Related News

24 Oct 2025, 18:41 UTC

Earnings

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 Oct 2025, 18:31 UTC

Earnings

Correction to Procter & Gamble to Focus on Innovation

24 Oct 2025, 16:25 UTC

Major Market Movers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 Oct 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Oct 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 Oct 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 Oct 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 Oct 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 Oct 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 Oct 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 Oct 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 Oct 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 Oct 2025, 18:52 UTC

Earnings

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:41 UTC

Earnings

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:03 UTC

Earnings

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 Oct 2025, 18:02 UTC

Earnings

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 Oct 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 Oct 2025, 16:57 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 Oct 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 Oct 2025, 16:44 UTC

Market Talk
Earnings

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 Oct 2025, 16:39 UTC

Market Talk
Earnings

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 Oct 2025, 16:33 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:23 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 16:07 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Pharma Mar SA Forecast

Price Target

By TipRanks

61.51% upside

12 Months Forecast

Average 120.002 EUR  61.51%

High 120 EUR

Low 120 EUR

Based on 1 Wall Street analysts offering 12 month price targets forPharma Mar SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

72.75 / 74.3Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
help-icon Live chat